ABSTRACT
Radiopharmaceuticals differ from normal medicines in that they have a short half-life. Due to the rapid decay, they must be prepared shortly before their clinical use and comprehensive quality control of the final product is not possible: sterility testing, for instance, cannot be performed due to time limits. Therefore, the safe and effective preparation and use of radiopharmaceuticals are vital for the protection of the operator and final user patient. The purpose of this review is to provide more detailed and practical guidance to those involved in the small-scale preparation of PET, therapeutic or other radiopharmaceuticals for commercial or distribution purposes.
Keywords:
Radiopharmaceuticals, quality assurance, PET, cGRPP
References
1
IAEA-TECDOC-1782. IAEA-TECDOC-1782 - Good Practice for Introducing Radiopharmaceuticals for Clinical Use 2016;65.
2
Decristoforo C. Challenges in the Small-Scale Preparation of Radiopharmaceuticals-A European Perspective. J Pharm Sci 2007;32:131-138.
3
Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2010;37:1049-1062.
4
Sağlık Bakanlığı. BEŞERİ Tibbi̇ Ürünler İmalathaneleri İyi̇ İmalat Uygulamalari (Gmp) Kılavuzu. 2018;2018:1-232.
5
Ayfer AA, Applied Basic Radiopharmacy, Ünak P, Durmuş Altun G, Teksöz S, Biber Müftüler FZ, editors. Nobel Tıp Kitapevi;2017. pp.179-185.
